{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:27:51Z","timestamp":1790393271490,"version":"4.1.0"},"reference-count":37,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"1","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002468","name":"Dong\u2010A University Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002468","name":"Dong-A University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">The response rate and survival improvement for rituximab, a CD20\u2010targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending the period of remission in MZL patients remains an essential goal. This multicenter, single\u2010arm, open\u2010label phase II study evaluated the survival efficacy of 2 years of rituximab\u2010maintenance therapy in patients with stage III\u2013IV CD20\u2010positive MZL who had responded to first\u2010line R\u2013CVP (rituximab, cyclophosphamide, vincristine, and prednisolone). The objective of this study was to determine whether rituximab maintenance following R\u2013CVP warrants further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Prior to rituximab\u2010maintenance therapy, patients received 6\u20138 cycles of first\u2010line R\u2013CVP therapy for stage III\u2013IV MZL. Rituximab (375 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), cyclophosphamide (750 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), and vincristine (1.4 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; maximum 2 mg) were administered via an intravenous infusion on day 1 of each 3\u2010week cycle, while oral prednisolone (100 mg) was given on days 1\u20135 of each 3\u2010week cycle. The patients who achieved complete response (CR), partial response (PR), or stable disease (SD) to R\u2013CVP treatment, were prescribed rituximab\u2010maintenance therapy which was administered intravenously at a dose of 375 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      every 8 weeks for up to 12 cycles. The primary endpoint was progression\u2010free survival (PFS). Secondary endpoints were overall survival (OS) and treatment safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      47 patients were enrolled, of whom, 45 (96%) received rituximab\u2010maintenance treatment. Fifteen (33%) patients had nodal MZL. Following R\u2013CVP first\u2010line therapy, 20 (44%), 22 (49%), and 3 (7%) patients achieved CR, PR, and SD, respectively. After a median follow\u2010up of 38.2 months, their observed 3\u2010year PFS rate was 81%. During the rituximab\u2010maintenance, 6 PR and 1 SD patients achieved CR following the administration of R\u2013CVP. Elevated LDH and the presence of B symptoms were found to be significant prognostic factors for PFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003) and demonstrated a 3\u2010year OS rate of 90%. Rituximab\u2010maintenance therapy was well tolerated, and the common treatment\u2010emergent adverse events were sensory neuropathy (18%), myalgia (13%), fatigue (9%), and neutropenia (9%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p xml:lang=\"en\">Rituximab\u2010maintenance therapy following first\u2010line R\u2013CVP demonstrated good PFS in patients with stage III\u2013IV MZL, in addition to a favorable toxicity profile.<\/jats:p>\n                    <jats:p xml:lang=\"en\">\n                      <jats:italic toggle=\"yes\">Trial registration<\/jats:italic>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>\n                      : NCT01213095\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40880-019-0403-7","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T11:10:13Z","timestamp":1571224213000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Phase II study of R\u2013CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study"],"prefix":"10.34133","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8321-4113","authenticated-orcid":false,"given":"Sung Yong","family":"Oh","sequence":"first","affiliation":[{"name":"Dong\u2010A University Hospital","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Yonsei University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[{"name":"Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok\u2010Hwan","family":"Yang","sequence":"additional","affiliation":[{"name":"Chonnam National University Hwasun Hospital","place":["Hwasun, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[{"name":"Busan Paik Hospital, Inje University College of Medicine","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Hallym University Sacred Heart Hospital, Hallym University College of Medicine","place":["Anyang, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho\u2010Young","family":"Yhim","sequence":"additional","affiliation":[{"name":"Chonbuk National University Hospital","place":["Jeonju, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Hyun","family":"Jeong","sequence":"additional","affiliation":[{"name":"Ajou University School of Medicine","place":["Suwon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Ho","family":"Won","sequence":"additional","affiliation":[{"name":"Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suee","family":"Lee","sequence":"additional","affiliation":[{"name":"Dong\u2010A University Hospital","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kong","sequence":"additional","affiliation":[{"name":"Wonju Severance Christian Hospital, Yonsei University College of Medicine","place":["Wonju, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung\u2010Nam","family":"Lim","sequence":"additional","affiliation":[{"name":"Haeundae Paik Hospital, Inje University College of Medicine","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ho","family":"Ji","sequence":"additional","affiliation":[{"name":"Samsung Changwon Hospital, Sungkyunkwan University School of Medicine","place":["Changwon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung A.","family":"Kwon","sequence":"additional","affiliation":[{"name":"Dongnam Institute of Radiological and Medical Sciences","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeong\u2010Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Gyeongsang National University Hospital, Gyeongsang National University College of Medicine","place":["Jinju, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Gachon University Gil Medical Center","place":["Incheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Sup","family":"Lee","sequence":"additional","affiliation":[{"name":"Kosin University Gospel Hospital, Kosin University College of Medicine","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho\u2010Jin","family":"Shin","sequence":"additional","affiliation":[{"name":"Pusan National University Hospital","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[{"name":"Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.4132\/koreanjpathol.2011.45.3.254"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/103.5.543"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712453595"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27773"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20874"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201012\u2010624296"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.08.002"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(03)14110\u20104"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.57"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1838"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg175"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201005\u2010021113"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.128"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012\u20100251"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102002\u201011\u20103496\u201011\u20103496"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24605"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2009.07677.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp395"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.04.003"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6272"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010011\u20101337\u20106"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.6994"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(14)00021\u20100"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201007\u2010795302"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(10)62175\u20107"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.509.509"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14007"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197\u20102456(89)90015\u20109"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.3968"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","unstructured":"Rummel MJ Koenigsmann M Chow KU Knauf W Lerchenmuller CA Losem C et al. Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B\u2010R) in patients with marginal zone lymphoma (MZL): results of a prospective randomized multicenter phase 2 study (the StiL NHL7\u20102008 MAINTAIN trial). J Clin Oncol. 2018;(Abstract 7515).","DOI":"10.1200\/JCO.2018.36.15_suppl.7515"},{"key":"e_1_3_2_37_2","unstructured":"Hoffmann\u2010La Roche A German Low Grade Lymphoma Study Group Institute of Cancer Research UK. A study of obinutuzumab (RO5072759) plus chemotherapy in comparison with rituximab plus chemotherapy followed by obinutuzumab or rituximab maintenance in patients with untreated advanced indolent non\u2010Hodgkin's lymphoma (GALLIUM). https:\/\/ClinicalTrials.gov\/show\/NCT01332968. Accessed 27 June 2018."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201002\u2010833608"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-019-0403-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40880-019-0403-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1186%2Fs40880-019-0403-7","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-019-0403-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1186\/s40880-019-0403-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:57:36Z","timestamp":1773824256000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1186\/s40880-019-0403-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1186\/s40880-019-0403-7"],"URL":"https:\/\/doi.org\/10.1186\/s40880-019-0403-7","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"2019-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"58"}}